[1] Lok AS,Zoulim F,Dusheiko G,et al.Hepatitis B cure:From discovery to regulatory approval. Hepatology,2017,66:1296-1313.
[2] Lok AS,Zoulim F,Dusheiko G,et al.Hepatitis B cure:From discovery to regulatory approval.J Hepatol,2017,67:847-861.
[3] Durantel D,Zoulim F.New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.Hepatology,2016,64:S117-S131.
[4] Lin CL,Yang HC,Kao JH,et al. Hepatitis B virus:new therapeutic perspectives.Liver Int,2016,36: 85-92.
[5] Su TH,Kao JH.Unmet Needs in Clinical and Basic Hepatitis B Virus Research.J Infect Dis,2017,216(suppl-8): S750-S756.
[6] Dawood A,Abdul BS,Jayaraj M,et al.Drugs in Development for Hepatitis B.Drugs,2017, 77:1263-1280.
[7] Testoni B,Durantel D,Zoulim F.Novel targets for hepatitis B virus therapy.Liver Int, 2017,37:33-39.
[8] Lin CL,Kao JH. Review article: novel therapies for hepatitis B virus cure-advances and perspectives.Aliment Pharmacol Ther,2016,44: 213-222.
[9] WHO Guidelines for the preventio,care and treatment of persons with chronic hepatitis B infection[EB/OL].(2015-03)[2015-05-01].http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/.
[10] Terrault NA,Bzowej NH,Chang KM et al.AASLD guidelines for treatment of chronic hepatitis B.Hepatology,2016,63: 261-283.
[11] Sarin SK,Kumar M,Lau GK,et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update.Hepatol Int,2016,10:1-98.
[12] Merriman RB,Tran TT.AASLD practice guidelines:The past,the present,and the future. Hepatology,2016,63: 31-34.
[13] Yuen MF,Liu K,Chan HL,et al.Prolonged RNA interference therapy with ARC-520 injection in treatment naive, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen.J Hepatol,2017,66(Suppl 1):S27.
[14] Wooddell CI,Yuen MF,Chan HL,et al.RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.Sci Transl Med,2017,27; 9(409).
[15] Kennedy EM, Bassit LC,Mueller H,et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology,2015,476:196-205.
[16] Hayakawa M,Umeyama H,Iwadate M,et al.Development of novel hepatitis B virus capsid inhibitor using in silico screening.Biochem Biophys Res Commun,2015,463: 1165-1175.
[17] Ohno M,Otsuka M,Kishikawa T,et al.Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection.Curr Opin Pharmacol,2016,30:131-137.
[18] Yuen MF,Kim DJ,Weilert F,et al.NVR3-778,a first-in-class HBV core inhibitor,alone and in combination with peg-interferon (PegIFN),in treatment naive HBeAg-positive patients:early reductions in HBV DNA and HBeAg.J Hepatol,2016,64(Suppl 1):S210-211.
[19] Buti M,Gane E,Seto WK,et al.Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negativechronic hepatitis B virus infection:a randomised, double-blind,phase 3,non-inferiority trial. Lancet Gastroenterol Hepatol,2016,: 196-206.
[20] Agarwal K,Fung S,Seto WK,et al.A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety resultsat week 96 [abstract no.ILC2017-RS-244]. In: International Liver Congress,2017,European Association for the study of the liver,Apr 2017,Amsterdam.
[21] Ye X,Zhou M,He Y,Tao S,et al. Efficient inhibition of hepatitis B virus infection by a preS1-binding peptide.Sci Rep,2016,07: 29391.
[22] Phillips S,Chokshi S,Chatterji U,et al.Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.Gastroenterology,2015,148: 403-414.e7.
[23] Pham EA,Perumpail RB,Fram BJ,et al.Future therapy for hepatitis B virus:role of immunomodulators.Curr Hepatol Rep,2016,15: 237-244.
[24] Park JJ, Wong DK, Wahed AS, et al. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B.Gastroenterology,2016,150: 684-695.
[25] Ye B, Liu X, Li X, Tcell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance.Cell Death Dis,2015,19:e1694.
[26] Buti M,Riveiro-Barciela M,Esteban R. Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection.J Infect Dis,2017,216: S792-S796.
[27] Jonathan Q,Catherine J,Madeleine B et al.Nucleic acid polymer REP 2139 and nucleos(t)ide analogues act synergistically against chronic hepadnaviral infection in vivo.Hepatology,2018, DOI:10.102/hep.29737. |
